Publications by authors named "Jinnie Ko"
Article Synopsis
- Patients with chronic rhinosinusitis with nasal polyps (CRSwNP) often experience sleep disturbances, which this study aimed to address by evaluating the effects of omalizumab on sleep quality and overall health.
- The analysis used data from the POLYP 1 and POLYP 2 clinical trials, assessing sleep through the Sino-Nasal Outcome Test-22 and other health status scales.
- Results showed significant improvements in sleep scores with omalizumab treatment after 24 and 52 weeks, indicating that it not only alleviates sinonasal symptoms but also enhances patients' sleep and overall well-being.
Background: Patients with chronic rhinosinusitis with nasal polyps (CRSwNP) often have atopic comorbidities, including elevated IgE levels and comorbid asthma. Omalizumab, an IgE monoclonal antibody, is an effective treatment for CRSwNP, but the impact of allergy or asthma status on response to omalizumab in patients with CRSwNP has not been well studied.
Objective: To evaluate the impact of allergy and asthma status on omalizumab treatment in patients with CRSwNP, this posthoc exploratory analysis assessed sinonasal outcomes from subgroups of patients included in POLYP 1 and POLYP 2 and the open-label extension (OLE) trials.
Acute and chronic cough are common symptoms in patients with severe allergic asthma. Although asthma-related cough can be controlled by asthma-specific medications, both prescription and over-the-counter antitussives are often also necessary. The anti-immunoglobulin E monoclonal antibody omalizumab is an effective treatment for patients with moderate-to-severe asthma, but little is known about subsequent antitussive use patterns.
View Article and Find Full Text PDFThese studies were conducted before clinical trial registration was required; therefore, clinical trial registration numbers are not available.
View Article and Find Full Text PDFIntroduction: Huntington's disease (HD) is a rare neurodegenerative disease characterized by cognitive, behavioral and motor symptoms that progressively worsen with time. Cognitive and behavioral signs of HD are generally present in the years prior to a diagnosis; however, manifest HD is typically assessed by genetic confirmation and/or the presence of unequivocal motor symptoms. Nevertheless, there is a large variation in symptom severity and rate of progression among individuals with HD.
View Article and Find Full Text PDFBackground: Effectiveness of asthma treatment, including biologics, may be different in patients with higher body mass index (BMI).
Objective: To evaluate response to omalizumab (dosed by serum immunoglobulin E level and weight) by BMI category.
Methods: Pooled data from 2 randomized, double-blind, placebo-controlled studies of adults with moderate-to-severe allergic asthma were analyzed by BMI category (<25 kg/m [normal or underweight], n = 397; 25 to <30 kg/m [overweight], n = 330; ≥ 30 kg/m [obese], n = 268).
Purpose: From 2011 to 2016, 13 randomized clinical trials with active controls were submitted to U.S. Food and Drug Administration (FDA) for the treatment of advanced melanoma.
View Article and Find Full Text PDFArticle Synopsis
- The study focused on nazartinib (EGF816), a third-generation EGFR tyrosine kinase inhibitor, aimed at patients with advanced non-small-cell lung cancer (NSCLC) who have specific EGFR mutations, including the Thr790Met mutation that contributes to treatment resistance.
- Conducted across nine academic centers, the phase 1 trial involved patients aged 18 and older with stage IIIB-IV EGFR-mutant NSCLC, assessing the safety and optimal dosage of nazartinib using a structured dose-escalation approach.
- By the end of August 2017, a total of 180 patients were treated, and while some dose-limiting toxicities were noted